<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03823703</url>
  </required_header>
  <id_info>
    <org_study_id>CORT118335-860</org_study_id>
    <nct_id>NCT03823703</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety, Efficacy, and Pharmacokinetics of CORT118335 in Patients With Probable Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of CORT118335 in Patients With Probable Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corcept Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2, double blind, placebo-controlled, randomized study is to access the safety and
      efficacy of CORT118335 in Patients with Probable Nonalcoholic Steatohepatitis (NASH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study that will assess the safety
      efficacy and PK of CORT118335 in in Patients with Probable Nonalcoholic Steatohepatitis
      (NASH).

      Patients who meet the criteria for the Study CORT118335-860 will be randomized on Day 1 to
      receive 600 mg CORT118335, or placebo for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Subject, Investigator and Outcomes Assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Relative change from Baseline to Week 12 in LFC (Liver fat content) assessed by MRI-PDFF comparing 600 mg CORT118335 to placebo.</measure>
    <time_frame>Baseline Day 1 to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of TEAEs from Baseline to Week 12 and during follow-up for 600 mg CORT118335 and placebo</measure>
    <time_frame>Up to week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in hematology from Baseline to Week 12 for 600 mg CORT118335 and placebo</measure>
    <time_frame>Baseline Day 1 to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in chemistry panel from Baseline to Week 12 for 600 mg CORT118335 and placebo</measure>
    <time_frame>Baseline Day 1 to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving a relative reduction in LFC (Liver fat content) of â‰¥30% by MRI-PDFF</measure>
    <time_frame>Baseline Day 1 to week 12</time_frame>
    <description>LFC assessed at week 12 for 600 mg CORT118335 versus placebo
LFC assessed at week 12 for 600 mg CORT118335 versus placebo LFC assessed at week 12 for 600 mg CORT118335 versus placebo
LFC assessed at week 12 for 600 mg CORT118335 versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in propeptide of type III collagen (pro-C3)</measure>
    <time_frame>Baseline Day 1 to week 12</time_frame>
    <description>Change in Pro-C for 600 mg CORT118335 versus placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>CORT118335- 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive 600 mg CORT118335, or placebo for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive 600 mg CORT118335, or placebo for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CORT118335</intervention_name>
    <description>CORT118335 600mg, and Placebo tablets for oral dosing</description>
    <arm_group_label>CORT118335- 600 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Miricorilant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of probable NASH with fibrosis defined by blood tests and scans

        Exclusion Criteria:

          -  Have participated in another clinical trial within the last 6 months where patient
             received active treatment for NASH

          -  Have participated in another clinical trial within the last 3 months

          -  Are pregnant or lactating females

          -  Have a BMI &lt;18 kg/m2

          -  Have had liver transplantation or plan to have liver transplantation during the study

          -  Have type 1 diabetes or poorly controlled type 2 diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ada Lee, MD</last_name>
    <role>Study Director</role>
    <affiliation>Corcept Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Lead</last_name>
    <phone>650-327-3270</phone>
    <email>study860ctgov@corcept.com</email>
  </overall_contact>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 14, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>September 6, 2019</last_update_submitted>
  <last_update_submitted_qc>September 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonalcoholic Steatohepatitis</keyword>
  <keyword>NASH</keyword>
  <keyword>Nonalcoholic Fatty Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

